Testosterone therapy for men
Testosterone therapy for men replaces testosterone by gel, injection or other route. Evidence is strong for diagnosed hypogonadism, where the Endocrine Society guideline recommends it, and not established for age-related decline in men with normal levels, where the guideline suggests against routine use in men 65 or older and the FDA keeps a limitation of use. The FDA added TRAVERSE trial results to labels in 2025 and found a class-wide blood pressure increase. Longevity clinics offer it more broadly than the evidence supports. Evidence tier: limited.
What it is
Testosterone therapy for men replaces testosterone with a prescribed gel, injection or other formulation. The evidence splits by who receives it. For men with diagnosed hypogonadism, meaning symptoms plus unequivocally low testosterone confirmed on two fasting morning measurements, the Endocrine Society guideline strongly recommends therapy, and the FDA labels these products for men who lack or have low testosterone with an associated medical condition. For age-related decline in men whose low levels come only from ageing, and for men whose levels are normal, no equivalent evidence base exists. The guideline suggests against routinely prescribing it to all men 65 or older and advises an individualized decision after explicit discussion of risks, and the FDA retains a limitation of use for age-related hypogonadism. Longevity and men's health clinics offer it more broadly. Because the use sold for longevity is the part the evidence does not establish, the tier on this page is limited. The FDA found that all testosterone products raise blood pressure, and the guideline advises against therapy in men planning fertility soon.
Who it is for
Men with diagnosed hypogonadism, with symptoms and consistently low morning testosterone, are the group for whom the Endocrine Society guideline strongly recommends therapy. Men over 65 with symptoms and consistently low levels may be offered it on an individualized basis after explicit discussion. The guideline suggests against routine treatment of all men 65 or older and advises against it for men planning fertility soon, and for those with certain cancers, elevated hematocrit or uncontrolled heart failure. Men with normal testosterone are not a group either source recommends treating.
What to expect
Diagnosis starts with total testosterone measured fasting on two separate mornings, then luteinizing hormone and follicle-stimulating hormone to separate causes. Formulations the guideline lists as approved include intramuscular injections, transdermal gels, patches, buccal tablets, subcutaneous pellets, an axillary solution and a nasal gel. After starting, the guideline calls for evaluating response, side effects and adherence, checking testosterone and hematocrit during the first year and holding therapy if hematocrit rises above 54 percent. It also calls for a prostate-specific antigen test and rectal exam at baseline and again 3 to 12 months in, with urology referral if PSA rises above set thresholds.
History and background
The Endocrine Society published its clinical practice guideline on testosterone therapy in men with hypogonadism in 2018. In February 2025 the FDA announced class-wide labeling changes: adding results of the TRAVERSE cardiovascular trial, submitted in 2023, to all testosterone labels, removing the cardiovascular language from the boxed warning, and adding a blood pressure warning. The FDA kept its limitation of use for age-related hypogonadism and its 2015 safety communication urging caution.
Worth knowing
The FDA states that testosterone products are approved solely for men who lack or have low testosterone in conjunction with an associated medical condition. The guideline notes that about 30 percent of men with an initial hypogonadal-range value have a normal repeat measurement, which is why it requires two morning tests. The TRAVERSE trial found no increase in adverse cardiovascular outcomes in men using testosterone for hypogonadism, which is the finding behind the FDA's labeling change, and it did not test testosterone as a longevity intervention.
Offered across the Atlas 4
Related modalities